Altimmune

[believer]

Onlangs goeie fase 2 resultaten gebracht, overname of deals in een miljardenmarkt, notering onder ALT

https://www.reuters.com/business/health ... 023-12-05/

[believer]

Goed lezen

https://www.marketbeat.com/originals/ca ... urce=snapi

[believer]

https://nl.marketscreener.com/koers/aan ... -45505962/

[believer]

https://www.reddit.com/r/Shortsqueeze/c ... rtnership/

[believer]

Drugs in the pipeline - including Lilly's retatrutide; Novo's CagriSema, a once-monthly injection in development at Amgen Inc. (AMGN); and Altimmune's pemvidutide - are "really, really exciting," Apovian said, because they're demonstrating great weight-loss benefits using some different mechanisms than drugs currently on the market."

[believer]

Altimmune is hier weer getipt https://finance.yahoo.com/news/16-most- ... 51260.html

[believer]

https://ir.altimmune.com/static-files/a ... d8b559fb78

[believer]

https://nypost.com/2024/01/13/lifestyle ... -suit/amp/

[believer]

In a Phase 2 study, a 2.4 milligram dose of Altimmune’s (NASDAQ:ALT) GLP 1 drug, pemvidutide, lowered participants’ weight by an average of 15.6% — 13.4 percentage points more than those taking a placebo. That compares very favorably with the results of a study of Eli Lilly’s (NYSE:LLY) popular GLP-1 drug, in which those taking the medicine lost an average of 7.1% more weight than those taking a placebo.

Also noteworthy is that pemvidutide’s tolerability was reportedly better than that of other GLP 1 treatments. Finally, the drug’s reduced LDL cholesterol more than two other popular GLP 1 drugs, semaglutide and tirzepatide.

Given these points, the $538 million market capitalization of ALT stock far undervalues the shares, while the company could easily become a takeover target.


https://www.nasdaq.com/articles/stocks- ... loss-drugs

[believer]

ALT Drug Better Than Ozempic!!!!!

https://m.youtube.com/live/K3vLw92uD5A

Biedstrijd kan starten voor de grote pharma bedrijven
https://finance.yahoo.com/quote/ALT/